KR20230125804A - 알츠하이머병의 치료를 위한 마시티닙 - Google Patents

알츠하이머병의 치료를 위한 마시티닙 Download PDF

Info

Publication number
KR20230125804A
KR20230125804A KR1020237023563A KR20237023563A KR20230125804A KR 20230125804 A KR20230125804 A KR 20230125804A KR 1020237023563 A KR1020237023563 A KR 1020237023563A KR 20237023563 A KR20237023563 A KR 20237023563A KR 20230125804 A KR20230125804 A KR 20230125804A
Authority
KR
South Korea
Prior art keywords
score
treatment
masitinib
pharmaceutically acceptable
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237023563A
Other languages
English (en)
Korean (ko)
Inventor
알랭 무씨
콜린 맨스필드
Original Assignee
에이비 사이언스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이비 사이언스 filed Critical 에이비 사이언스
Publication of KR20230125804A publication Critical patent/KR20230125804A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237023563A 2020-12-16 2021-12-16 알츠하이머병의 치료를 위한 마시티닙 Pending KR20230125804A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20306589 2020-12-16
EP20306589.1 2020-12-16
PCT/EP2021/086308 WO2022129410A1 (en) 2020-12-16 2021-12-16 Masitinib for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
KR20230125804A true KR20230125804A (ko) 2023-08-29

Family

ID=74141317

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237023563A Pending KR20230125804A (ko) 2020-12-16 2021-12-16 알츠하이머병의 치료를 위한 마시티닙

Country Status (10)

Country Link
US (1) US20240058328A1 (https=)
EP (1) EP4262801A1 (https=)
JP (1) JP2023554354A (https=)
KR (1) KR20230125804A (https=)
CN (1) CN116963736A (https=)
AU (1) AU2021399925A1 (https=)
CA (1) CA3201259A1 (https=)
IL (1) IL303521A (https=)
MX (1) MX2023007029A (https=)
WO (1) WO2022129410A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025113494A1 (zh) * 2023-11-27 2025-06-05 浙江径科医药有限公司 多环类化合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05001277A (es) 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
US8153792B2 (en) 2007-02-13 2012-04-10 Ab Science Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
AR080380A1 (es) * 2010-03-09 2012-04-04 Ab Science Tratamiento de la demencia tipo alzheimer con masitinib

Also Published As

Publication number Publication date
EP4262801A1 (en) 2023-10-25
IL303521A (en) 2023-08-01
WO2022129410A1 (en) 2022-06-23
CN116963736A (zh) 2023-10-27
AU2021399925A1 (en) 2023-06-29
CA3201259A1 (en) 2022-06-23
MX2023007029A (es) 2023-07-18
JP2023554354A (ja) 2023-12-27
US20240058328A1 (en) 2024-02-22
AU2021399925A9 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
JP7080944B2 (ja) 細胞生存率を向上させるための組成物およびその使用方法
CN108883108B (zh) 马赛替尼用于治疗肌萎缩侧索硬化症患者亚群的用途
US20180311236A1 (en) Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease
KR20190045273A (ko) 치매 치료
CA2601509A1 (en) Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions
JP7788154B2 (ja) 多発性硬化症患者の亜集団の処置のためのマシチニブ
US20170119760A1 (en) Use of masitinib for the treatment of progressive supranuclear palsy
KR20230125804A (ko) 알츠하이머병의 치료를 위한 마시티닙
JP2006516629A (ja) 置換キノリンおよび置換ジフェニルスルホンを含有する組成物および方法
JP2012121890A (ja) 神経接続欠陥、例えば精神分裂病及び自閉症の治療においてエポチロン（ｅｐｏｔｈｉｌｏｎｅ）を使用する方法
JP5386478B2 (ja) パーキンソン病に伴う運動不全の治療のための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用
KR20050121236A (ko) 치매 환자에서 초조 증상을 치료하기 위한 카르바마제핀유도체의 용도
ES2963706T3 (es) Masitinib para el tratamiento del cáncer de próstata resistente a la castración
AU2018258970B2 (en) Idalopirdine-based combinatorial therapies of Alzheimer's disease
CZ2003234A3 (cs) 2-Aryl-8-oxodihydropurinové deriváty jako léčivo
JP2011020957A (ja) アルツハイマー病治療薬
HK1261581B (zh) 马赛替尼用於治疗肌萎缩侧索硬化症患者亚群的用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230711

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241127

Comment text: Request for Examination of Application